Comprehensive Evidence-Based Management of Heart Failure

For heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%), immediately initiate quadruple therapy with SGLT2 inhibitor, ACE inhibitor (or ARNI), beta-blocker, and mineralocorticoid receptor antagonist (MRA), as this combination reduces mortality and hospitalizations more effectively than any single agent alone 1, 2.

Heart Failure with Reduced Ejection Fraction (HFrEF)

Foundational Pharmacotherapy (Quadruple Therapy)

The 2022 AHA/ACC/HFSA guidelines establish four medication classes as cornerstone therapy 1:

1. SGLT2 Inhibitors (Class I recommendation)

Start dapagliflozin 10 mg daily or empagliflozin 10 mg daily
Initiate regardless of diabetes status
Can be started simultaneously with other GDMT, no need for sequential titration
Benefits appear within weeks to months

2. ACE Inhibitors or ARNI (Class I recommendation)

First-line: Start ACE inhibitor (e.g., enalapril 2.5 mg twice daily, lisinopril 2.5-5 mg daily)
Titrate to target doses: enalapril 10-20 mg twice daily, lisinopril 20-40 mg daily
Upgrade to ARNI: Replace ACE inhibitor with sacubitril/valsartan (starting 24-49 mg/26-51 mg twice daily, target 97/103 mg twice daily) in patients who remain symptomatic despite optimal ACE inhibitor therapy 3
Wait 36 hours after last ACE inhibitor dose before starting ARNI to avoid angioedema

3. Beta-Blockers (Class I recommendation)

Evidence-based agents: carvedilol, metoprolol succinate, or bisoprolol
Start low: carvedilol 3.125 mg twice daily, metoprolol succinate 12.5-25 mg daily
Titrate to target: carvedilol 25-50 mg twice daily, metoprolol succinate 200 mg daily
Uptitrate every 2 weeks as tolerated 3

4. Mineralocorticoid Receptor Antagonists (Class I recommendation)

Spironolactone 12.5-25 mg daily or eplerenone 25 mg daily
Target: spironolactone 25-50 mg daily, eplerenone 50 mg daily
Monitor potassium and creatinine within 1 week, then monthly for 3 months 1
Hold if potassium >5.5 mEq/L or creatinine rises substantially

Critical Implementation Strategy

Initiate all four drug classes within 6-12 weeks of diagnosis 4. Do not wait for sequential titration—start multiple agents simultaneously at low doses, then uptitrate. This "horizontal" approach (starting all classes early) outperforms "vertical" approach (maximizing one drug before adding another).

Diuretic Management

Loop diuretics are essential for congestion but do not improve survival 3:

Use furosemide 20-40 mg daily (or equivalent) for volume overload
Titrate to achieve euvolemia: no peripheral edema, no orthopnea, no elevated JVP
If inadequate response: increase dose, give twice daily, or add thiazide (metolazone 2.5-5 mg)
Avoid thiazides if eGFR <30 mL/min unless combined with loop diuretic 5
Monitor electrolytes and renal function closely with aggressive diuresis

Secondary Therapies for Persistent Symptoms

Ivabradine (if sinus rhythm, heart rate ≥70 bpm despite beta-blocker):

Start 2.5-5 mg twice daily, target 7.5 mg twice daily
Reduces hospitalizations in selected patients 1

Hydralazine/Isosorbide Dinitrate (especially for Black patients or ACE inhibitor intolerance):

Hydralazine 37.5 mg three times daily + isosorbide dinitrate 20 mg three times daily
Target: hydralazine 75 mg + isosorbide dinitrate 40 mg three times daily
Proven mortality benefit in Black patients 1

Vericiguat (for recent worsening HF):

Start 2.5 mg daily, target 10 mg daily
Consider if hospitalization or IV diuretics within 6 months despite GDMT 1

Digoxin (for persistent symptoms or atrial fibrillation):

0.125-0.25 mg daily (lower in elderly, renal dysfunction)
Improves symptoms but does not reduce mortality 5
Target serum level 0.5-0.9 ng/mL

Device Therapy

Implantable Cardioverter-Defibrillator (ICD) 3:

Primary prevention: LVEF ≤35% despite ≥3 months optimal medical therapy, NYHA Class II-III, expected survival >1 year
Not indicated within 40 days post-MI (no survival benefit)
Secondary prevention: Survivors of ventricular arrhythmia causing hemodynamic instability

Cardiac Resynchronization Therapy (CRT) 3:

Class I: LVEF ≤35%, sinus rhythm, LBBB with QRS ≥150 ms, NYHA Class II-IV on optimal therapy
Reduces mortality and hospitalizations
Consider CRT-D (with defibrillator) vs CRT-P (pacemaker only) based on sudden death risk

Common Pitfalls to Avoid

Do not use diltiazem or verapamil—they worsen HF and increase hospitalizations 3
Avoid triple neurohormonal blockade (ACE inhibitor + ARB + MRA)—excessive hyperkalemia and renal dysfunction risk 3
Do not stop GDMT if LVEF improves (HFimpEF)—continue all medications as discontinuation leads to relapse 1
Avoid NSAIDs—cause sodium retention and attenuate ACE inhibitor effects 5

Heart Failure with Nonreduced Ejection Fraction (HFnrEF: LVEF >40%)

The 2025 Canadian guidelines now unify HFmrEF (LVEF 41-49%) and HFpEF (LVEF ≥50%) under "HFnrEF" because they respond similarly to therapy 2.

Pharmacotherapy for HFnrEF

1. SGLT2 Inhibitors (Strongest recommendation) 2, 6:

First-line therapy: Dapagliflozin 10 mg daily or empagliflozin 10 mg daily
Class 2a recommendation (2022 AHA/ACC for HFpEF) 1
Reduces HF hospitalizations and cardiovascular death
Benefits consistent across LVEF >40% spectrum

2. Mineralocorticoid Receptor Antagonists 2, 6:

Spironolactone 15-45 mg daily (TOPCAT trial dosing)
Finerenone (non-steroidal MRA): 20-40 mg daily—emerging evidence from FINEARTS-HF shows reduced HF events 7, 8
Class 2b recommendation 1
Monitor potassium closely

3. Angiotensin Receptor-Neprilysin Inhibitors (ARNI) 2, 6:

Sacubitril/valsartan 24-49 mg/26-51 mg twice daily, target 97/103 mg twice daily
Class 2b recommendation 1
Greatest benefit in LVEF 41-49% range (lower end of HFnrEF spectrum)

4. GLP-1 Receptor Agonists (Emerging therapy) 2, 7, 8:

Semaglutide 2.4 mg weekly (STEP-HFpEF trials): improves symptoms, exercise capacity, weight loss in obesity-associated HFpEF
Tirzepatide (SUMMIT trial): similar benefits
Consider especially in obese patients (BMI ≥30) with HFpEF

5. Angiotensin Receptor Blockers 1:

Candesartan 4-32 mg daily or losartan 25-100 mg daily
Class 2b recommendation
Alternative if ARNI not tolerated

Diuretics for HFnrEF

Use loop diuretics judiciously for congestion 6:

Start furosemide 20-40 mg daily as needed
Titrate to relieve symptoms, but avoid excessive diuresis (can worsen diastolic filling)
Monitor for hypotension and renal dysfunction

Comorbidity Management (Critical for HFnrEF)

Hypertension (Class I recommendation) 1, 3:

Target BP <130/80 mmHg
Use GDMT agents (SGLT2i, ARNI, MRA) as antihypertensives

Atrial Fibrillation (Class 2a recommendation) 1:

Rate control: beta-blockers or digoxin (avoid non-dihydropyridine calcium channel blockers)
Rhythm control: consider catheter ablation in selected patients
Anticoagulation per CHA₂DS₂-VASc score

Obesity:

Weight loss ≥10% improves symptoms and exercise capacity
Consider GLP-1 agonists (semaglutide, tirzepatide) 7, 8

Diabetes:

SGLT2 inhibitors provide dual benefit (glycemic control + HF outcomes)
Avoid thiazolidinediones (rosiglitazone, pioglitazone)—cause fluid retention 1

Coronary Artery Disease:

Revascularization if ischemia-driven HF
Standard antiplatelet therapy

Chronic Kidney Disease:

Continue SGLT2 inhibitors even with eGFR 20-45 mL/min (renal protection)
Adjust MRA doses, monitor potassium

Therapies to Avoid in HFnrEF

Nitrates and phosphodiesterase-5 inhibitors (sildenafil): No benefit, potential harm 1
Routine beta-blockers (unless specific indication: prior MI, angina, AF): May impair exercise tolerance due to chronotropic incompetence 6

Lifestyle and Non-Pharmacologic Management

Exercise and Cardiac Rehabilitation

Structured exercise training is recommended for all stable HF patients 5:

Do not prescribe rest—leads to deconditioning
Aerobic exercise 30 minutes, 5 days/week
Cardiac rehabilitation programs (NYHA Class II-III): improve symptoms, exercise capacity, quality of life
Continue daily physical activities to prevent muscle deconditioning

Dietary Recommendations

Sodium restriction 5:

Limit to 2-3 grams/day in symptomatic HF
More aggressive restriction (<2 g/day) in severe HF with persistent congestion
Teach patients to read labels, avoid processed foods

Fluid management:

Restrict fluids to 1.5-2 L/day in severe HF with hyponatremia or refractory congestion
Daily weights: report gain >2 kg in 3 days

Alcohol:

Avoid excessive intake (>2 drinks/day)
Complete abstinence if alcohol-induced cardiomyopathy

Smoking Cessation

Mandatory recommendation 5:

Nicotine replacement therapy, varenicline, or bupropion
Smoking worsens HF progression

Patient Education and Self-Management

Essential components 5:

Explain HF pathophysiology and symptom recognition
Daily weight monitoring: call if gain >2 kg in 3 days
Medication adherence: explain rationale for each drug
Recognize worsening symptoms: increased dyspnea, orthopnea, edema, fatigue
Prognosis discussion and advance care planning

Monitoring and Follow-Up

Laboratory Monitoring

After initiating/titrating GDMT 5:

Check potassium, creatinine, BP within 1-2 weeks
Repeat at 3 months, then every 6 months if stable
Hold MRA if K+ >5.5 mEq/L; restart at lower dose when K+ <5.0 mEq/L
Stop ACE inhibitor/ARNI if creatinine rises >30% from baseline; reassess volume status and diuretic dose

Natriuretic Peptides

BNP or NT-proBNP 5:

Useful for diagnosis (high negative predictive value)
Trending values can guide diuretic therapy
Elevated levels indicate increased risk of hospitalization/death

Echocardiography

Repeat TTE 3:

At 3-6 months after initiating GDMT to assess LVEF response
Before ICD/CRT consideration (must document LVEF ≤35% on optimal therapy ≥3 months)
If clinical deterioration or new murmur (assess for valvular disease)

Special Populations and Considerations

Cardiac Amyloidosis

New screening recommendations 1:

Serum/urine monoclonal light chains (rule out AL amyloidosis)
Technetium pyrophosphate scan (diagnose ATTR amyloidosis)
Genetic sequencing if ATTR confirmed (distinguish hereditary vs wild-type)
Tafamidis (TTR stabilizer): reduces mortality in ATTR-CM
Anticoagulation even without AF (high thromboembolic risk)

Improved LVEF (HFimpEF)

Continue all GDMT even if LVEF improves to >40% 1:

Discontinuation leads to relapse in 40% of patients
Maintain quadruple therapy indefinitely

Acute Decompensated Heart Failure

Immediate management:

IV loop diuretics: furosemide 40-80 mg IV bolus, then continuous infusion if needed
Oxygen/non-invasive ventilation for hypoxemia
Identify and treat precipitants: ACS, hypertensive emergency, arrhythmia, infection, medication non-adherence
Avoid routine vasodilators (nitrates)—limited mortality benefit 3
Transition to oral GDMT before discharge; do not wait for "stability"

Cardiogenic Shock

Advanced therapies:

Inotropes (dobutamine, milrinone): temporary bridge, no mortality benefit
Mechanical circulatory support (Impella, ECMO): bridge to recovery or transplant
Early cardiology/HF specialist consultation

Summary Algorithm for HF Management

HFrEF (LVEF ≤40%):

Initiate quadruple therapy immediately: SGLT2i + ACE inhibitor (or ARNI) + beta-blocker + MRA
Add loop diuretic for congestion
Uptitrate to target doses within 6-12 weeks
Reassess at 3 months: If LVEF ≤35% on optimal therapy, consider ICD/CRT
If persistent symptoms: Add ivabradine, hydralazine/isosorbide dinitrate, vericiguat, or digoxin

HFnrEF (LVEF >40%):

Start SGLT2 inhibitor (first-line)
Add MRA (spironolactone or finerenone)
Consider ARNI if LVEF 41-49% or persistent symptoms
Diuretics as needed for congestion
Optimize comorbidities: hypertension, diabetes, obesity, AF, CAD
GLP-1 agonists if obese (BMI ≥30)

All HF Patients:

Sodium restriction, daily weights, exercise rehabilitation
Smoking cessation, medication adherence
Monitor potassium, creatinine, BP regularly
Patient education and self-management support

What is the comprehensive evidence‑based management of chronic heart failure, including pharmacologic therapy for reduced ejection fraction, treatment options for preserved ejection fraction, diuretic strategies, lifestyle recommendations, and device therapy?

Have a follow-up question?